Goldpac Group Limited at its annual general meeting held on May 18, 2017, approved the appointment of Mr. WU Siqiang as an executive Director. The shareholders also approved the appointment of Ms. YE Lu as an independent non-executive Director. Mr. Christophe Jacques PAGEZY was not re-elected at the AGM and thus retired as a non-executive Director with effect from the conclusion of the AGM. As a result of his retirement, Mr. PAGEZY also ceased to be a member of nomination committee of the Company upon the conclusion of the AGM. The following Directors have tendered their resignations to the Company and their resignations took effect at the conclusion of the AGM: Mr. TING Tao I has resigned as a non-executive Director and ceased to act as a member of the remuneration committee of the Company as he intends to devote more time to other business commitments; and Mr. ZHU Lijun has resigned as an independent non-executive Director and ceased to act as a member of each of the audit committee and the nomination committee of the company as he intends to devote more time to his family and personal affairs. The board announced that, Dr. LING Wai Lim has been appointed by the Board as a non-executive Director of the company after the conclusion of the AGM. Dr. LING has been the project manager of China Regenerative Medicine International Limited, since September 2016, in which he served as a project analyst from June 2015 to August 2016. The Board announced that the composition of the Board Committees of the company has been changed as follows: Mr. LU Run Ting has been appointed by the Board as a member of the remuneration committee; Mr. HOU Ping has been appointed by the Board as a member of the nomination committee; and Ms. YE Lu has been appointed by the Board as a member of the audit committee and nomination committee.